Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
CN¥ 7.48
Key Takeaways
Risk factor
Good trading liquidity
Data is available to registered users only
Data is available to registered users only
Profitability factor
Favourable price performance
Data is available to registered users only
Data is available to registered users only
About
Zhejiang Hisoar Pharmaceutical Co., Ltd., a pharmaceutical company, produces and sells fine chemicals and special raw drugs in China and internationally. It offers antibiotic, anti-virus, cardiovascular, sugar-reducing, and other materials; and medicine intermediates, and other customized and processed products, such as clindamycin, 4-AA Iso-carbapenem series, thiamphenicol, florfenicol, voglibose, eclindamycin, 4-AA iso-carbapenem, thiamphenicol, florfenicol, voglibose, etc....
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. In particular, the stock is 'expensive' on EV/EBITDA.
Data is available to registered users only
